Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Costain shares tank as first-half revenues drop 18%

(Sharecast News) - Shares in Costain plummeted on Wednesday despite the construction and engineering firm hiking its dividend, as revenues in the first half dropped by almost a fifth. The company reported revenues of £525.4m for the six months to 30 June, down 17.8% over last year, as growth in the Natural Resources division was outweighed by falls in Transportation from expected road project completions and a rephased schedule from HS2.

However, Costain said that an improved quality of contracts and strong operational execution helped drive a 3.1% increase in adjusted operating profit to £16.8m.

The adjusted operating margin rose to 3.2% from 2.5% last year, with the company "confident" in delivering its run-rate target of 4.5% over 2025.

The company said it ended the half with a "strong balance sheet", though net cash declined to £144.9m from £158.5m at the end of 2024. However, this is expected to improve to £170m by the year-end.

The interim dividend was raised to 1.0p, up from just 0.4p last year, though this reflected a more balanced dividend split between the first and second halves.

"We continue to win new work and add new customers in growth markets that provide essential infrastructure, expanding our forward work position to £5.6bn, more than four times FY 24 revenue. We have already secured 90% of our forecast revenue for the year and our bidding activity levels remain high," said chief executive Alex Vaughn.

Looking ahead, the company said that improvements in the market outlook and its positioning "underpin our confidence in delivering on our expectations for further progress in FY 25 and FY 26, with a step change in performance expected in FY 27 and beyond".

Despite the bullish outlook, shares were down 15.5% at 138p by 0905 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.